Statins as Neuroinflammatory Therapy, Bibliometric Study

ARMAN YURISALDI SALEH; Tirta Darmawan Susanto; Riezky Valentina; Dwi Arwandi Yogi Saputra

doi:10.12688/f1000research.152963.1

Home Browse Statins as Neuroinflammatory Therapy, Bibliometric Study

ALL Metrics

-

Views

-

Downloads

Get PDF

Get XML

Export

▬

✚

Systematic Review

Statins as Neuroinflammatory Therapy, Bibliometric Study

[version 1; peer review: awaiting peer review]

ARMAN YURISALDI SALEH ¹, Tirta Darmawan Susanto², Riezky Valentina¹, Dwi Arwandi Yogi Saputra³

PUBLISHED 23 Aug 2024

Author details Author details

¹ Neurology, Universitas Pembangunan Nasional Veteran Jakarta, Jakarta, Special Capital Region of Jakarta, 12450, Indonesia
² Family Medicine and Primary Care, Universitas Pelita Harapan, Tangerang, Banten, Indonesia
³ Public Health Sciences, Universitas Pembangunan Nasional Veteran Jakarta, Jakarta, Special Capital Region of Jakarta, 12450, Indonesia

ARMAN YURISALDI SALEH
Roles: Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Investigation, Methodology, Project Administration, Resources, Software, Supervision, Validation, Visualization, Writing – Original Draft Preparation

Tirta Darmawan Susanto
Roles: Writing – Original Draft Preparation, Writing – Review & Editing

Riezky Valentina
Roles: Writing – Review & Editing

Dwi Arwandi Yogi Saputra
Roles: Writing – Review & Editing

OPEN PEER REVIEW

REVIEWER STATUS AWAITING PEER REVIEW

This article is included in the Neuroinflammation collection.

Abstract

Introduction

Neuroinflammase, a key mechanism in neurodegenerative diseases like Alzheimer and Parkinson, is influenced by statin, a lipid-binding protein. Studies show that statin can mitigate the likelihood of developing dementia and Alzheimer’s disease and can also reduce leukocytosis and T-regulatory function. Nevertheless, there is restricted literature on the use of statin in neuroinflammation. The objective of this investigation is to conduct a bibliometric analysis of statin use in neuroinflammation, providing valuable insights into research development and future research questions.

Methods

In this work, a literature review methodology is employed to gather data from the Scopus database using the keywords neuroinflammation and statins. Data were analyzed using Biblioshiny and VOSviewer software to produce visualizations and bibliometric maps. We conducted quantitative and qualitative analysis.

Results

The research trend found are Documents by Year, Most Global Cited Document, Most Relevant Sources, Factorial Map Of The Documents With The Highest Contributes, Documents by Author, Most Relevant Affiliations, Documents by Subject Area, Trend Topic, Network Visualization, Overlay visualization of scopus, database using Vosviewer, Density Visualization, Thematic Map, Thematic Evolution, Cluster Analysis, Qualitative Analysis, and Word Cloud.

Conclusions

The study highlights the potential for further research on statins and neuroinflammation, aiming to better understand their role in treating neuroinflammation and enhance the quality of life for patients with neuroinflammatory conditions.

Keywords

statin, therapy, neuroinflammation, trend, niche, bibliometric

Corresponding author: ARMAN YURISALDI SALEH

Competing interests: No competing interests were disclosed.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2024 SALEH AY et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite: SALEH AY, Susanto TD, Valentina R and Saputra DAY. Statins as Neuroinflammatory Therapy, Bibliometric Study [version 1; peer review: awaiting peer review]. F1000Research 2024, 13:959 (https://doi.org/10.12688/f1000research.152963.1) First published: 23 Aug 2024, 13:959 (https://doi.org/10.12688/f1000research.152963.1) Latest published: 23 Aug 2024, 13:959 (https://doi.org/10.12688/f1000research.152963.1)

Introduction

Neuroinflammation serves as a significant secondary mechanism in pathological conditions affecting the nervous system, such as Alzheimer’s disease and Parkinson’s disease. Statins, a class of pharmaceutical agents that reduce lipid levels, have exhibited neuroprotective properties in diverse experimental models of neuroinflammation. Nevertheless, there is a lack of bibliometric research investigating the utilization of statins in relation to neuroinflammation. Statins have broad anti-inflammatory and immunomodulatory effects. Some studies have shown that statin use can reduce the risk of dementia or Alzheimer’s. In addition, other studies show that statins can reduce leukocyte invasion of the brain and increase the proportion of regulatory T cells, which play an important role in modulating the immune response. Therefore, understanding how statins can be used to control neuroinflammation may open new avenues in the treatment of neurological diseases.

Although there is evidence indicating the therapeutic potential of statins in neuroinflammation, there remains a significant lack of research in this area. Most previous research has focused on the effects of statins in experimental models, and little research has been conducted in human patients. Additionally, no bibliometric studies have examined this topic, which means that we do not yet have a comprehensive understanding of research developments in this field.

Bibliometric studies are a very useful tool for understanding research developments in a particular field. By analyzing previous research publications, we can identify research trends, knowledge gaps, and areas that require further research. In the context of statin use in neuroinflammation, bibliometric studies can help us understand how far this topic has been researched and what we still need to know.

Therefore, the aim of this study was to perform a bibliometric analysis of statin use in neuroinflammation. We hope that the results of this study will provide a better picture of research developments in this area and will help formulate research questions for future studies.

In the management of hypercholesterolemia and cardiovascular disease, statins have been extensively employed. Statins primarily function by inhibiting the enzyme HMG-CoA reductase, which is involved in the manufacture of cholesterol. Recent studies have demonstrated that statins possess anti-inflammatory and immunomodulatory properties. Statins have exhibited neuroprotective effects in different experimental models within the framework of neuroinflammation.

Methods

Bibliometric research is a research method that uses scientific publication data to describe and analyze the development of a field of science. This research aims to identify and map trends, patterns, and relationships between scientific documents related to certain topics. In this research, the topic chosen was school feeding and stunting. This research uses data from the website www.scopus.com, which is one of the largest and most trusted databases for scientific publications. This research was conducted in March 2024.

To carry out bibliometric research, the steps to follow are as follows:

1. Determine search keywords. In this research, the keywords used are neuroinflammation, and statin. These keywords are entered into the search column on the www.scopus.com site by selecting the topic field (title, abstract, keywords).
2. Filter search results. In this study, Were not filtered.
3. Retrieve the data from the search results. This study involves the retrieval of search result data in three distinct formats, namely:
- • CSV (comma-separated value), which contains basic information about the document, such as title, author, affiliation, year, source, abstract, and keywords.
- • RIS (research information system), which contains detailed information about a document, including the references cited by the document.

Data collection

A search was conducted on the Scopus website using the specified terms, with the understanding that this platform encompasses research that is deemed to possess validity: TITLE – ABS – KEY (neuroinflammation) AND TITLE – ABS – KEY (statin) are the titles of the products that are under consideration. Ninety eight documents were received by us. You then save the document from Scopus in the form of a file with the extension.csv following this step.

Data analysis

Both the Biblioshiny and Vosviewer software packages were utilised in the analysis process.

Quantitative analysis

Documents by year

Figure 1. Documents by year.

Based on Figure 1, it appears that there has been an increase in the number of documents, until in 2021 there are 12 documents. The oldest document was in 2002, titled, Interactions of Aβ with endogenous anti-inflammatory agents: A basis for chronic neuroinflammation in Alzheimer’s disease, writings by Janciauskiene, S. Sun, Y.-X. Wright, H.T.¹ Meanwhile, the latest document in 2024 is entitled Targeting the CCL2–CCR2 signaling pathway: potential implications of statins beyond cardiovascular diseases, written Gholamalizadeh, H. Ensan, B. Sukhorukov, V.N. Sahebkar, A.²

Most global cited document

Figure 2. Most global cited documents.

Based on Figure 2, the document that received the most citations, with 224 citations, was the document written by Greenwood, J. Walters, C.E. Pryce, G. Baker, D. Adamson, P with title Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis.³ Which was published in the journal The FASEB journal: official publication of the Federation of American Societies for Experimental Biology. In the next position, with 204 citations, is a journal written Alam, A. Hana, Z. Jin, Z. Suen, K.C. Ma, D., in 2018 in the EBioMedicine Journal entitled Surgery, neuroinflammation and cognitive impairment.⁴ In third place with 141 citations are written documents Xu X, in 2017 in Journal of Neuroinflammation entitled Anti-inflammatory and immunomodulatory mechanisms of atorvastatin in a murine model of traumatic brain injury.⁵

Most relevant sources

Figure 3. Most relevant sources.

Based on Figure 3, the following are the journals that publish the most important documents. Neuroinflammation is the journal that is ranked first in producing the most documents. The Neuroinflammation Journal is in quartile 1 (Q1) for the Cellular and Molecular Neuroscience and Immunology categories in 2022. The SJR (SCImago Journal Rank) value for the Neuroinflammation Journal in 2022 is 2,439. Neuroinflammation has been indexed in Scopus since 2004. Types of articles published: This journal contains various types of articles such as research and reviews. The main focus of this journal is the interaction of the immune system (especially the innate immune system) with the nervous system. The Journal of Neuroinflammation is published by BioMed Central Ltd. The median time from submission to first editorial decision for all manuscripts was 29 days, and the median time from submission to acceptance was 145 days.

In second place is the journal Brain Research. Brain Research journal was in quartile 2 (Q2) for the Molecular Biology and Developmental Biology category in 2022. Brain Research journal has been indexed in Scopus since 1966. The journal publishes original research articles reporting interesting interdisciplinary investigations of the structure and function of the nervous system for the international community of neuroscientists. In addition, the journal also publishes invited reviews. The Brain Research journal is published by Elsevier.

In third place is CNS Neurological Disorders - Drug Targets. - The last quartile of this journal is Q2. Based on Scopus data, the SJR (SCImago Journal Rank) of this journal is 0.574. This journal has been indexed in Scopus since 2006. The journal publishes thematic issues edited by leaders in the field covering a wide range of current topics from CNS & neurological drug targets. The journal also accepts publication of original research articles, letters, reviews, and drug trial studies. This journal is published by Bentham Science Publishers B.V. Publication times may vary depending on factors such as the complexity of the research and the editorial team’s current workload. Journals typically ask reviewers to submit their reviews within 3-4 weeks.

Factorial map of the documents with the highest contributes

Figure 4. Factorial map of the documents with the highest contributes.

In Figure 4, the following is a factorial map of the documents with the highest contributions based on title. The document that contributes most to cluster 1 is the one written by Gu M in 2021 entitled Neurotoxicity and Underlying Mechanisms of Endogenous Neurotoxins. The document that contributes most to cluster 2 is the one written by Sing I in 2018 entitled Impaired peroxisomal function in the central nervous system with inflammatory disease of experimental autoimmune encephalomyelitis animals and protection by lovastatin treatment.

Documents by author

Figure 5. Documents by author.

Based on Figure 5, the three most frequent authors each with three documents are as follows: Adamson, P with the title of the article: Pharmacological targeting of ICAM-1 signaling in brain endothelial cells: Potential for treating neuroinflammation,⁶ How do statins control neuroinflammation?,⁷ Lovastatin inhibits brain endothelial cell Rhomediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis.³

Greenwood, J with the title: Pharmacological targeting of ICAM-1 signaling in brain endothelial cells: Potential for treating neuroinflammation,⁶ How do statins control neuroinflammation?,⁷ Lovastatin inhibits brain endothelial cell Rhomediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis.³

Prediger, R.D. with the title of the article: Atorvastatin Prevents Early Oxidative Events and Modulates Inflammatory Mediators in the Striatum Following Intranasal 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Administration in Rats,⁸ Succinobucol, a Non-Statin Hypocholesterolemic Drug, Prevents Premotor Symptoms and Nigrostriatal Neurodegeneration in an Experimental Model of Parkinson’s Disease,⁹ Atorvastatin improves cognitive, emotional and motor impairments induced by intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in rats, an experimental model of Parkinson’s disease.¹⁰

Most relevant affiliations

Figure 6. Most relevant affiliations.

Based on Figures 6, 7, affiliates produce the most documents Medical University of South Carolina with 4 documents and further College of Medicine, Universidade de São Paulo, UCL Institute of Ophthalmology, Imperial College London, Universidade Federal de Santa Catarina, University College London and Fundacao Oswaldo Cruz with 3 documents each.

Documents by subject area

Figure 7. Documents by subject area.

Trend topic

Figure 8. Trend topic.

Based on Figure 8, trend topics in 2021 are related to the keyword hemorrhage.

Network visualization

Figure 9. Network visualization.

Based on Figure 9, it can be seen that the areas studied are still not related to other areas that are divided into edges. That’s the field: rats,wistar, neuroprotective agent, protein bax, maze test, treatment duration, in vivo study, cell proliferation, pitavastatin, human cell, cytology, autacoid, mevalonic acid, central nervous system, enzyme inhibition, apolipoprotein e, disease course, Alzheimer disease, nonsteroid, anti inflammatory ag, risk factor, brain blood flow, placebo, gelatinase b, major clinical study, treatment outcome, caspase 3.

Overlay visualization of scopus, database using Vosviewer

Figure 10. Overlay visualization of scopus, database using Vosviewer.

Based on Figure 10, in the overlay visualization, it appears that the keywords that have been researched a lot approaching 2018 are the part colored yellow, namely: sepsis, complication, cognitive defect, protein blood level, hippocampus, male, brain haemorrhage, nervous system inflammation, animal, statin, pathophysiology, glia cell and metabolism.

Density visualization

Figure 11. Density visualization.

Based on Figure 11, in the visual circulation density, it appears that the part that is already saturated with research is yellow, while the part that is not yet saturated is slightly yellow and dominantly green, namely keywords.: protein bax, neuroprotective agent, rats,wistar, neuroprotective agents, caspase 3, complication, mase test, treatment duration, mice, inbred c57bl, c57bl mouse, gene expression, cytology, human cell, immunology, encephalomyelitis, autoimmune, cell proliferation, experimental autoimmune enceph, allergic encephalyelitis, mevalonic acid, pitavastatin, enzyme inhibiton, central nervous system, mevalonic acid, hydroxymethylglutaril ceoenzyme, apolipopprotein e, disease course, alzheimer’s disease, amyloid precursor protein, nonsteroid antiinfllammatory ag, risk factor, pathogenesis, risk factors, pathophysiology, brain blood flow, placebo, low drug dose, gelatinase b, major clinical study, c reactive protein, encephalitis, macrophage, glia cell, mortality, brain ischemia, brain haemorrhage, treatment outcome, blood-brain barrier, and cognitive dysfunction.

Thematic map

Figure 12. Thematic map.

Based on Figure 12, based on the thematic map, it appears that the niche themes or themes that are still little researched and have just emerged are the keywords cells, pathway and anti-inflammatory, drug and treatment. The themes that are already saturated and are starting to be abandoned by researchers are themes with the keywords atorvastatin, cognitive, rat, apart from that are experimental, autoimmune, encephalomyelitis, and the themes neuroinflammation, potential, hemorrhage.

Thematic evolution

Figure 13. Thematic evolution.

Based on Figure 13, thematic evolution in 2002-2018 are the keywords delirium, disease, statins, atorvastatin, experimental and model. The theme then changed in 2019-2024 to autoimmune, disease, statins, neuroinflammation, atorvastatin, simvastatin, mode, drug.

Cluster analysis

2 The result of cluster analysis [See extended data⁹²] [See extended data⁹²] [See extended data⁹²]

From 2 5 clusters based on keywords. [See extended data⁹²]

Cluster 1, dominated by Hydroxymethylglutaryl coenzyme a reductase inhibitor drugs, Human, Humans.

Cluster 2, dominated by Nonhuman, Article, Animals.

Cluster 3, dominated by Nervous system inflammation, Neuroinflammation, Microglia.

Cluster 4, dominated by Animal, Metabolism, Male.

Cluster 5, dominated by Inflammation, Atorvastatin, Anti-inflammatory activity.

Qualitative analysis

Diseases for which statins are applied:

1. Cardiovascular diseases²^,⁷
2. Alzheimer’s¹¹^–²³
3. Multiple Sclerosis²⁴^,²⁵
4. Dyskinesia²⁶
5. Autoimmune encephalomyelitis³^,²⁷^–³³
6. Aneurysmal subarachnoid haemorrhage³⁴
7. Stroke³⁵^,³⁶
8. Sars-CoV-2³⁷
9. Intracerebral Hemorrhage³⁸^–⁴³
10. Autoimmune diseases, rheumatoid arthritis, and inflammatory bowel diseases
11. Delirium⁴⁴^–⁴⁸
12. Neurodegeneration⁴⁹^–⁵³
13. Huntington’s Disease⁵⁴
14. Diabetes-related depression⁵⁵^,⁵⁶
15. Sepsis⁵⁷
16. Traumatic Brain Injury⁵^,⁵⁸^,⁵⁹
17. Dementia⁶⁰^,⁶¹
18. Myasthenia gravis⁶²
19. Cognitive impairment⁶³^–⁶⁸
20. Epilepsy⁶⁹^–⁷⁴
21. Parkinson’s⁸^,¹⁰
22. Scrapie-infected mice⁷⁵
23. Inflammatory conditions⁷⁶
24. Restore morphine’s antinociceptive effect, inhibit astrocyte activation, and reduce TNFα and IL-1β expression⁷⁷
25. Antioxidant, anti-inflammatory, and anti-apoptotic properties, contributing to their clinical efficacy in treating neurological disorders⁷⁸
26. Does not specifically discuss statins¹^,⁴^,⁶^,⁹^,⁷⁹^–⁹¹

Word cloud

Figure 14. Word cloud.

Based on Figure 14, word cloud shows that the dominant word in the document is the word children and what follows is statins, disease, atorvastatin and alzheimers.

Discussion

This bibliometric study shows that research on statins as neuroinflammatory therapies has advanced rapidly in recent years. However, there are still some areas that have not been widely researched and are emerging, such as cells, pathways, anti-inflammatories, drugs, and treatments. These themes show great potential for further research. For example, research on cells and pathways can help us understand the mechanisms underlying the anti-inflammatory effects of statins. Additionally, research on drugs and treatments can help us develop more effective treatment strategies.

On the other hand, some themes seem to have become saturated and are starting to be abandoned by researchers. These include atorvastatin, cognitive, mouse, experimental, autoimmune, encephalomyelitis, neuroinflammatory, potential, and hemorrhage. Although these themes have been widely researched, they still have importance. For example, research on atorvastatin has provided valuable insight into the neuroprotective effects of statins. Additionally, research on neuroinflammation and bleeding potential has helped us understand the pathogenesis of various neurological conditions.

However, the research focus appears to be shifting towards new themes. This may reflect changes in our understanding of neuroinflammation and the role of statins in its treatment. One of the important findings of this study is that research on statins and neuroinflammation is very mixed. It covers a wide range of fields, from cellular biology to clinical pharmacology. Additionally, this study also shows that research on statins and neuroinflammation has been conducted throughout the world. This reflects the importance of this topic in global medical research.

However, there are still several challenges to be faced. For example, although research on cells and pathways has increased, there is still much we need to know about the mechanisms underlying the anti-inflammatory effects of statins. Additionally, although research on drugs and treatments has progressed, there is still a need for larger and better-designed clinical studies. However, despite these challenges, the results of this study show that there are many opportunities for further research. By focusing on new themes and addressing existing challenges, we can hope to make significant progress in research on statins and neuroinflammation.

Overall, this study provides a comprehensive overview of current research on statins and neuroinflammation. By identifying new themes and highlighting under-researched areas, this study can help determine future research directions. However, it is important to remember that bibliometric studies like this have limitations. For example, they depend on the availability of publications and the quality of their indexation. Therefore, the results of this study should be interpreted with caution.

Nonetheless, this study shows that research on statins and neuroinflammation is an active and growing field. By continuing to monitor developments in this field, we can hope to better understand the role of statins in the treatment of neuroinflammation. Finally, further research is needed to fully understand the potential of statins as neuroinflammatory therapies. By focusing on new themes and exploring under-researched areas, we can hope to make significant progress in this research.

Conclusion

In conclusion, this study suggests that there are many opportunities for further research on statins and neuroinflammation. By tapping into new themes and exploring under-researched areas, we can hope to better understand the role of statins in the treatment of neuroinflammation and, ultimately, improve the quality of life for patients with neuroinflammatory conditions.

Author contribution

AYS conducts research, gathers data, performs statistical analysis, and produces discussions and conclusions, RV and DAYS editing.

Data availability statement

Underlying data

Figshare: Statins as Neuroinflammatory Therapy, Bibliometric Study, https://doi.org/10.6084/m9.figshare.26002228.v5.⁹²

The project contains the following underlying data:

• BIBLIOMETRIC SCOPUS Statin as Neuroinflammatory Therapy, Bibliometric Study (ARTICLE).csv (Data (.csv) from www.scopus.com for bibliometric research the effect of statin as neuroinflammatory therapy).

Data are available under the terms of the Creative Commons Zero “No rights reserved” data waiver (CC BY 4.0 Public domain dedication).

Extended data

Figshare: Statins as Neuroinflammatory Therapy, Bibliometric Study, https://doi.org/10.6084/m9.figshare.26002228.v5.⁹²

The project contains the following extended data

• Table 1. Documents by subject area
• Table 2. The result of cluster analysis

Data are available under the terms of the Creative Commons Zero “No rights reserved” data waiver (CC BY 4.0 Public domain dedication).

Reporting guidelines

Figshare: Statins as Neuroinflammatory Therapy, Bibliometric Study, https://doi.org/10.6084/m9.figshare.26002438.v2.⁹³

The project contains the following data:

○ PRISMA checklist & Flow Diagram

Data are available under the terms of the Creative Commons Zero “No rights reserved” data waiver (CC BY 4.0 Public domain dedication).

Software availability

VOSviewer software is an open-access tool that can be used as a cost-effective method for any scientometric analysis.⁹⁴

References

1. Janciauskiene S, Sun YX, Wright HT: Interactions of A beta with endogenous anti-inflammatory agents: a basis for chronic neuroinflammation in Alzheimer’s disease. Neurobiol. Dis. 2002; 10(3): 187–200. PubMed Abstract | Publisher Full Text
2. Gholamalizadeh H, Ensan B, Sukhorukov VN, et al.: Targeting the CCL2-CCR2 signaling pathway: potential implications of statins beyond cardiovascular diseases. J. Pharm. Pharmacol. 2024; 76(2): 138–153. PubMed Abstract | Publisher Full Text
3. Greenwood J, Walters CE, Pryce G, et al.: Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis. FASEB J. 2003; 17(8): 905–907. PubMed Abstract | Publisher Full Text
4. Alam A, Hana Z, Jin Z, et al.: Surgery, neuroinflammation and cognitive impairment. EBioMedicine. 2018; 37: 547–556. PubMed Abstract | Publisher Full Text | Free Full Text
5. Xu X, Gao W, Cheng S, et al.: Anti-inflammatory and immunomodulatory mechanisms of atorvastatin in a murine model of traumatic brain injury. J. Neuroinflammation. 2017; 14(1): 167. PubMed Abstract | Publisher Full Text | Free Full Text
6. Turowski P, Adamson P, Greenwood J: Pharmacological targeting of ICAM-1 signaling in brain endothelial cells: potential for treating neuroinflammation. Cell. Mol. Neurobiol. 2005; 25(1): 153–170. PubMed Abstract | Publisher Full Text
7. Adamson P, Greenwood J: How do statins control neuroinflammation? Inflamm. Res. 2003; 52(10): 399–403. Publisher Full Text
8. Marques NF, Castro AA, Mancini G, et al.: Atorvastatin Prevents Early Oxidative Events and Modulates Inflammatory Mediators in the Striatum Following Intranasal 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Administration in Rats. Neurotox. Res. 2018; 33(3): 549–559. PubMed Abstract | Publisher Full Text
9. Santos DB, Colle D, Moreira EL, et al.: Succinobucol, a Non-Statin Hypocholesterolemic Drug, Prevents Premotor Symptoms and Nigrostriatal Neurodegeneration in an Experimental Model of Parkinson’s Disease. Mol. Neurobiol. 2017; 54(2): 1513–1530. PubMed Abstract | Publisher Full Text
10. Castro AA, Wiemes BP, Matheus FC, et al.: Atorvastatin improves cognitive, emotional and motor impairments induced by intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in rats, an experimental model of Parkinson’s disease. Brain Res. 2013; 1513: 103–116. PubMed Abstract | Publisher Full Text
11. Zhou X, Wu X, Wang R, et al.: Mechanisms of 3-Hydroxyl 3-Methylglutaryl CoA Reductase in Alzheimer’s Disease. Int. J. Mol. Sci. 2023; 25(1). PubMed Abstract | Publisher Full Text | Free Full Text
12. Weekman EM, Johnson SN, Rogers CB, et al.: Atorvastatin rescues hyperhomocysteinemia-induced cognitive deficits and neuroinflammatory gene changes. J. Neuroinflammation. 2023; 20(1): 199. PubMed Abstract | Publisher Full Text | Free Full Text
13. Zahedi E, Sanaeierad A, Nikbakhtzadeh M, et al.: Simvastatin improves learning and memory impairment via gut-brain axis regulation in an ovariectomized/D-galactose Alzheimer’s rat model. Behav. Brain Res. 2023; 453: 114611. PubMed Abstract | Publisher Full Text
14. Alsubaie N, Al-Kuraishy HM, Al-Gareeb AI, et al.: Statins Use in Alzheimer Disease: Bane or Boon from Frantic Search and Narrative Review. Brain Sci. 2022; 12(10). PubMed Abstract | Publisher Full Text | Free Full Text
15. Arbo BD, Schimith LE, Goulart Dos Santos M, et al.: Repositioning and development of new treatments for neurodegenerative diseases: Focus on neuroinflammation. Eur. J. Pharmacol. 2022; 919: 174800. PubMed Abstract | Publisher Full Text
16. Gamba P, Giannelli S, Staurenghi E, et al.: The Controversial Role of 24-S-Hydroxycholesterol in Alzheimer’s Disease. Antioxidants (Basel). 2021; 10(5). Publisher Full Text
17. Sallustio F, Studer V: Targeting New Pharmacological Approaches for Alzheimer’s Disease: Potential for Statins and Phosphodiesterase Inhibitors. CNS Neurol. Disord. Drug Targets. 2016; 15(6): 647–659. PubMed Abstract | Publisher Full Text
18. Xia W, Mo H: Potential of tocotrienols in the prevention and therapy of Alzheimer’s disease. J. Nutr. Biochem. 2016; 31: 1–9. PubMed Abstract | Publisher Full Text
19. de la Monte SM : Therapeutic targets of brain insulin resistance in sporadic Alzheimer’s disease. Front. Biosci. (Elite Ed.). 2012; 4(4): 1582–1605. PubMed Abstract | Publisher Full Text
20. Pac-Soo C, Lloyd DG, Vizcaychipi MP, et al.: Statins: the role in the treatment and prevention of Alzheimer’s neurodegeneration. J. Alzheimers Dis. 2011; 27(1): 1–10. PubMed Abstract | Publisher Full Text
21. Giunta B, Rezai-Zadeh K, Tan J: Impact of the CD40-CD40L dyad in Alzheimer’s disease. CNS Neurol. Disord. Drug Targets. 2010; 9(2): 149–155. PubMed Abstract | Publisher Full Text | Free Full Text
22. Scarpini E, Cogiamanian F: Alzheimer’s disease: from molecular pathogenesis to innovative therapies. Expert. Rev. Neurother. 2003; 3(5): 619–630. Publisher Full Text
23. Silva T, Teixeira J, Remião F, et al.: Alzheimer’s disease, cholesterol, and statins: the junctions of important metabolic pathways. Angew. Chem. Int. Ed. Engl. 2013; 52(4): 1110–1121. PubMed Abstract | Publisher Full Text
24. Alruwaili M, Al-Kuraishy HM, Alexiou A, et al.: Pathogenic Role of Fibrinogen in the Neuropathology of Multiple Sclerosis: A Tale of Sorrows and Fears. Neurochem. Res. 2023; 48(11): 3255–3269. PubMed Abstract | Publisher Full Text | Free Full Text
25. Luccarini I, Ballerini C, Biagioli T, et al.: Combined treatment with atorvastatin and minocycline suppresses severity of EAE. Exp. Neurol. 2008; 211(1): 214–226. PubMed Abstract | Publisher Full Text
26. Lopez-Lopez A, Valenzuela R, Rodriguez-Perez AI, et al.: Interactions between Angiotensin Type-1 Antagonists, Statins, and ROCK Inhibitors in a Rat Model of L-DOPA-Induced Dyskinesia. Antioxidants (Basel). 2023; 12(7). Publisher Full Text
27. Vigne S, Duc D, Peter B, et al.: Lowering blood cholesterol does not affect neuroinflammation in experimental autoimmune encephalomyelitis. J. Neuroinflammation. 2022; 19(1): 42. PubMed Abstract | Publisher Full Text | Free Full Text
28. Prado DS, Damasceno LEA, Sonego AB, et al.: Pitavastatin ameliorates autoimmune neuroinflammation by regulating the Treg/Th17 cell balance through inhibition of mevalonate metabolism. Int. Immunopharmacol. 2021; 91: 107278. PubMed Abstract | Publisher Full Text
29. Singh I, Samuvel DJ, Choi S, et al.: Combination therapy of lovastatin and AMP-activated protein kinase activator improves mitochondrial and peroxisomal functions and clinical disease in experimental autoimmune encephalomyelitis model. Immunology. 2018; 154(3): 434–451. PubMed Abstract | Publisher Full Text | Free Full Text
30. de Oliveira DM , de Oliveira EM , Ferrari Mde F, et al.: Simvastatin ameliorates experimental autoimmune encephalomyelitis by inhibiting Th1/Th17 response and cellular infiltration. Inflammopharmacology. 2015; 23(6): 343–354. PubMed Abstract | Publisher Full Text
31. Murugesan N, Paul D, Lemire Y, et al.: Active induction of experimental autoimmune encephalomyelitis by MOG35-55 peptide immunization is associated with differential responses in separate compartments of the choroid plexus. Fluids Barriers CNS. 2012; 9(1): 15. PubMed Abstract | Publisher Full Text | Free Full Text
32. Paintlia AS, Paintlia MK, Singh AK, et al.: Inhibition of rho family functions by lovastatin promotes myelin repair in ameliorating experimental autoimmune encephalomyelitis. Mol. Pharmacol. 2008; 73(5): 1381–1393. PubMed Abstract | Publisher Full Text | Free Full Text
33. Singh I, Paintlia AS, Khan M, et al.: Impaired peroxisomal function in the central nervous system with inflammatory disease of experimental autoimmune encephalomyelitis animals and protection by lovastatin treatment. Brain Res. 2004; 1022(1-2): 1–11. PubMed Abstract | Publisher Full Text
34. Xu B, Zhou Y, Zhang Z, et al.: Serum concentrations of NLRP3 in relation to functional outcome and delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. Clin. Chim. Acta. 2022; 536: 61–69. PubMed Abstract | Publisher Full Text
35. Mir MA, Albaradie RS: Inflammatory Mechanisms as Potential Therapeutic Targets in Stroke. Adv. Neuroimmune Biol. 2014; 5: 199–216. Publisher Full Text
36. Simani L, Naderi N, Khodagholi F, et al.: Association of Long-Term Atorvastatin with Escalated Stroke-Induced Neuroinflammation in Rats. J. Mol. Neurosci. 2017; 61(1): 32–41. PubMed Abstract | Publisher Full Text
37. Gonçalves CA, Sesterheim P, Wartchow KM, et al.: Why antidiabetic drugs are potentially neuroprotective during the Sars-CoV-2 pandemic: The focus on astroglial UPR and calcium-binding proteins. Front. Cell. Neurosci. 2022; 16: 905218. PubMed Abstract | Publisher Full Text | Free Full Text
38. Zhang J, Hao N, Li W, et al.: Simvastatin Upregulates Lipoxin A4 and Accelerates Neuroinflammation Resolution After Intracerebral Hemorrhage. Curr. Neurovasc. Res. 2022; 19(3): 321–332. PubMed Abstract | Publisher Full Text
39. Zhang R, Xue M, Yong VW: Central Nervous System Tissue Regeneration after Intracerebral Hemorrhage: The Next Frontier. Cells. 2021; 10(10). PubMed Abstract | Publisher Full Text | Free Full Text
40. Zi L, Zhou W, Xu J, et al.: Rosuvastatin Nanomicelles Target Neuroinflammation and Improve Neurological Deficit in a Mouse Model of Intracerebral Hemorrhage. Int. J. Nanomedicine. 2021; 16: 2933–2947. PubMed Abstract | Publisher Full Text | Free Full Text
41. Zhang J, Shi X, Hao N, et al.: Simvastatin Reduces Neutrophils Infiltration Into Brain Parenchyma After Intracerebral Hemorrhage via Regulating Peripheral Neutrophils Apoptosis. Front. Neurosci. 2018; 12: 977. PubMed Abstract | Publisher Full Text | Free Full Text
42. Indraswari F, Wang H, Lei B, et al.: Statins improve outcome in murine models of intracranial hemorrhage and traumatic brain injury: a translational approach. J. Neurotrauma. 2012; 29(7): 1388–1400. PubMed Abstract | Publisher Full Text
43. James RF, Kramer DR, Aljuboori ZS, et al.: Novel Treatments in Neuroprotection for Aneurysmal Subarachnoid Hemorrhage. Curr. Treat. Options Neurol. 2016; 18(8): 38. Publisher Full Text
44. Chen J, Wang Y, Hu X, et al.: The Role of Statins in the Management of Delirium: Recent Advances. CNS Neurol. Disord. Drug Targets. 2021; 20(3): 203–215. PubMed Abstract | Publisher Full Text
45. Mariscalco G, Mariani S, Biancari F, et al.: Effects of statins on delirium following cardiac surgery - evidence from literature. Psychiatr. Pol. 2015; 49(6): 1359–1370. PubMed Abstract | Publisher Full Text
46. Taburyanskaya M, Hassig T: Statins and delirium: is there a role? Curr. Atheroscler. Rep. 2015; 17(1): 470. PubMed Abstract | Publisher Full Text
47. Page VJ, Davis D, Zhao XB, et al.: Statin use and risk of delirium in the critically ill. Am. J. Respir. Crit. Care Med. 2014; 189(6): 666–673. PubMed Abstract | Publisher Full Text | Free Full Text
48. Morandi A, Hughes CG, Girard TD, et al.: Statins and brain dysfunction: a hypothesis to reduce the burden of cognitive impairment in patients who are critically ill. Chest. 2011; 140(3): 580–585. PubMed Abstract | Publisher Full Text | Free Full Text
49. Catalão CHR, Santos-Junior NN, da Costa LHA , et al.: Simvastatin Prevents Long-Term Cognitive Deficits in Sepsis Survivor Rats by Reducing Neuroinflammation and Neurodegeneration. Neurotox. Res. 2020; 38(4): 871–886. PubMed Abstract | Publisher Full Text
50. McFarland AJ, Davey AK, McDermott CM, et al.: Differences in statin associated neuroprotection corresponds with either decreased production of IL-1β or TNF-α in an in vitro model of neuroinflammation-induced neurodegeneration. Toxicol. Appl. Pharmacol. 2018; 344: 56–73. PubMed Abstract | Publisher Full Text
51. Clementino AR, Marchi C, Pozzoli M, et al.: Anti-Inflammatory Properties of Statin-Loaded Biodegradable Lecithin/Chitosan Nanoparticles: A Step Toward Nose-to-Brain Treatment of Neurodegenerative Diseases. Front. Pharmacol. 2021; 12: 716380. PubMed Abstract | Publisher Full Text | Free Full Text
52. Bagheri H, Ghasemi F, Barreto GE, et al.: The effects of statins on microglial cells to protect against neurodegenerative disorders: A mechanistic review. Biofactors. 2020; 46(3): 309–325. PubMed Abstract | Publisher Full Text
53. Ian HH, Joanne R, Stephane H, et al.: STAREE-Mind Imaging Study: a randomised placebo-controlled trial of atorvastatin for prevention of cerebrovascular decline and neurodegeneration in older individuals. BMJ Neurol. Open. 2023; 5(2): e000541. Publisher Full Text
54. González-Guevara E, Cárdenas G, Pérez-Severiano F, et al.: Dysregulated Brain Cholesterol Metabolism Is Linked to Neuroinflammation in Huntington’s Disease. Mov. Disord. 2020; 35(7): 1113–1127. PubMed Abstract | Publisher Full Text
55. Hai-Na Z, Xu-Ben Y, Cong-Rong T, et al.: Atorvastatin ameliorates depressive behaviors and neuroinflammatory in streptozotocin-induced diabetic mice. Psychopharmacology. 2020; 237(3): 695–705. PubMed Abstract | Publisher Full Text
56. Yu XB, Zhang HN, Dai Y, et al.: Simvastatin prevents and ameliorates depressive behaviors via neuroinflammatory regulation in mice. J. Affect. Disord. 2019; 245: 939–949. PubMed Abstract | Publisher Full Text
57. de Jesus Oliveira FM , Gonçalves-de-Albuquerque CF, de Moraes IMM , et al.: Simvastatin Posttreatment Controls Inflammation and Improves Bacterial Clearance in Experimental Sepsis. Mediat. Inflamm. 2020; 2020: 1839762.
58. Lokhandwala A, Hanna K, Gries L, et al.: Preinjury Statins Are Associated With Improved Survival in Patients With Traumatic Brain Injury. J. Surg. Res. 2020; 245: 367–372. PubMed Abstract | Publisher Full Text
59. Wible EF, Laskowitz DT: Statins in traumatic brain injury. Neurotherapeutics. 2010; 7(1): 62–73. PubMed Abstract | Publisher Full Text | Free Full Text
60. Barus R, Béné J, Deguil J, et al.: Drug interactions with dementia-related pathophysiological pathways worsen or prevent dementia. Br. J. Pharmacol. 2019; 176(18): 3413–3434. PubMed Abstract | Publisher Full Text | Free Full Text
61. Petek B, Villa-Lopez M, Loera-Valencia R, et al.: Connecting the brain cholesterol and renin-angiotensin systems: potential role of statins and RAS-modifying medications in dementia. J. Intern. Med. 2018; 284(6): 620–642. PubMed Abstract | Publisher Full Text
62. Li X-L, Li H, Zhang M, et al.: Correction to: Exosomes derived from atorvastatin-modified bone marrow dendritic cells ameliorate experimental autoimmune myasthenia gravis by up-regulated levels of IDO/Treg and partly dependent on FasL/Fas pathway. J. Neuroinflammation. 2019; 16(1): 119. PubMed Abstract | Publisher Full Text | Free Full Text
63. Ekladious ST, El Sayed NS: Effect of pioglitazone and simvastatin in lipopolysaccharide-induced amyloidogenesis and cognitive impairment in mice: possible role of glutamatergic pathway and oxidative stress. Behav. Pharmacol. 2019; 30(1): 5–15. PubMed Abstract | Publisher Full Text
64. Fang SC, Xie H, Chen F, et al.: Simvastatin ameliorates memory impairment and neurotoxicity in streptozotocin-induced diabetic mice. Neuroscience. 2017; 355: 200–211. PubMed Abstract | Publisher Full Text
65. Reis PA, Estato V, da Silva TI , et al.: Statins decrease neuroinflammation and prevent cognitive impairment after cerebral malaria. PLoS Pathog. 2012; 8(12): e1003099. PubMed Abstract | Publisher Full Text | Free Full Text
66. Kurata T, Miyazaki K, Kozuki M, et al.: Atorvastatin and pitavastatin improve cognitive function and reduce senile plaque and phosphorylated tau in aged APP mice. Brain Res. 2011; 1371: 161–170. PubMed Abstract | Publisher Full Text
67. Reis PA, Alexandre PCB, D’Avila JC, et al.: Statins prevent cognitive impairment after sepsis by reverting neuroinflammation, and microcirculatory/endothelial dysfunction. Brain Behav. Immun. 2017; 60: 293–303. PubMed Abstract | Publisher Full Text
68. Xu TC, Lv Y, Liu QY, et al.: Long-term atorvastatin improves cognitive decline by regulating gut function in naturally ageing rats. Immun. Ageing. 2022; 19(1): 52. PubMed Abstract | Publisher Full Text | Free Full Text
69. Quintana-Pájaro LJ, Ramos-Villegas Y, Cortecero-Sabalza E, et al.: The Effect of Statins in Epilepsy: A Systematic Review. J. Neurosci. Rural Pract. 2018; 9(4): 478–486. PubMed Abstract | Publisher Full Text
70. Jin Z, Jung Y, Yi CO, et al.: Atorvastatin pretreatment attenuates kainic acid-induced hippocampal neuronal death via regulation of lipocalin-2-associated neuroinflammation. Korean J. Physiol. Pharmacol. 2018; 22(3): 301–309. PubMed Abstract | Publisher Full Text | Free Full Text
71. Oliveira CV, Grigoletto J, Canzian JM, et al.: Effect of atorvastatin on behavioral alterations and neuroinflammation during epileptogenesis. Epilepsy Behav. 2018; 78: 109–117. PubMed Abstract | Publisher Full Text
72. Shafaroodi H, Moezi L, Fakhrzad A, et al.: The involvement of nitric oxide in the anti-seizure effect of acute atorvastatin treatment in mice. Neurol. Res. 2012; 34(9): 847–853. PubMed Abstract | Publisher Full Text
73. Gouveia TL, Scorza FA, Iha HA, et al.: Lovastatin decreases the synthesis of inflammatory mediators during epileptogenesis in the hippocampus of rats submitted to pilocarpine-induced epilepsy. Epilepsy Behav. 2014; 36: 68–73. PubMed Abstract | Publisher Full Text
74. Dar K, Kapucu A, Acar S, et al.: Evaluation of Antiepileptogenic Effect of Atorvastatin on Development of Pentylenetetrazole Induced Kindling in Rats: The Responsibility of Inducible Nitric Oxide Synthase and Metalloproteinase 2. Turk. Klin. J. Med. Sci. 2013; 33: 995–1006. Publisher Full Text
75. Carroll JA, Race B, Phillips K, et al.: Statins are ineffective at reducing neuroinflammation or prolonging survival in scrapie-infected mice. J. Gen. Virol. 2017; 98(8): 2190–2199. PubMed Abstract | Publisher Full Text | Free Full Text
76. McFarland AJ, Davey AK, Anoopkumar-Dukie S: Statins Reduce Lipopolysaccharide-Induced Cytokine and Inflammatory Mediator Release in an in vitro Model of Microglial-Like Cells. Mediat. Inflamm. 2017; 2017: 2582745.
77. Li W, Li Y, Zhu S, et al.: Rosuvastatin attenuated the existing morphine tolerance in rats with L5 spinal nerve transection through inhibiting activation of astrocytes and phosphorylation of ERK42/44. Neurosci. Lett. 2015; 584: 314–319. PubMed Abstract | Publisher Full Text
78. Farooqui AA, Ong WY, Horrocks LA, et al.: Comparison of biochemical effects of statins and fish oil in brain: the battle of the titans. Brain Res. Rev. 2007; 56(2): 443–471. PubMed Abstract | Publisher Full Text
79. Mohamed DI, Alaa El-Din Aly El-Waseef D, Nabih ES, et al.: Acetylsalicylic Acid Suppresses Alcoholism-Induced Cognitive Impairment Associated with Atorvastatin Intake by Targeting Cerebral miRNA155 and NLRP3: In Vivo, and In Silico Study. Pharmaceutics. 2022; 14(3). PubMed Abstract | Publisher Full Text | Free Full Text
80. Ong WY, Go ML, Wang DY, et al.: Effects of Antimalarial Drugs on Neuroinflammation-Potential Use for Treatment of COVID-19-Related Neurologic Complications. Mol. Neurobiol. 2021; 58(1): 106–117. PubMed Abstract | Publisher Full Text | Free Full Text
81. Ma G, Pan Z, Kong L, et al.: Neuroinflammation in hemorrhagic transformation after tissue plasminogen activator thrombolysis: Potential mechanisms, targets, therapeutic drugs and biomarkers. Int. Immunopharmacol. 2021; 90: 107216. PubMed Abstract | Publisher Full Text
82. Tauber SC, Djukic M, Gossner J, et al.: Sepsis-associated encephalopathy and septic encephalitis: an update. Expert Rev. Anti-Infect. Ther. 2021; 19(2): 215–231. PubMed Abstract | Publisher Full Text
83. Starhof C, Hejl AM, Korbo L, et al.: Risk of Multiple System Atrophy and the Use of Anti-Inflammatory Drugs: A Danish Register-Based Case-Control Study. Neuroepidemiology. 2020; 54(1): 58–63. PubMed Abstract | Publisher Full Text
84. Nasoohi S, Simani L, Khodagholi F, et al.: Coenzyme Q10 supplementation improves acute outcomes of stroke in rats pretreated with atorvastatin. Nutr. Neurosci. 2019; 22(4): 264–272. PubMed Abstract | Publisher Full Text
85. Shetty AK, Upadhya R, Madhu LN, et al.: Novel Insights on Systemic and Brain Aging, Stroke, Amyotrophic Lateral Sclerosis, and Alzheimer’s Disease. Aging Dis. 2019; 10(2): 470–482. PubMed Abstract | Publisher Full Text | Free Full Text
86. Marcuzzi A, Piscianz E, Zweyer M, et al.: Geranylgeraniol and Neurological Impairment: Involvement of Apoptosis and Mitochondrial Morphology. Int. J. Mol. Sci. 2016; 17(3): 365. PubMed Abstract | Publisher Full Text | Free Full Text
87. Celsi F, Piscianz E, Romano M, et al.: Knockdown of MVK does not lead to changes in NALP3 expression or activation. J. Inflamm. (Lond). 2015; 12: 7. PubMed Abstract | Publisher Full Text | Free Full Text
88. Korn T, Rao M, Magnus T: Autoimmune modulation of astrocyte-mediated homeostasis. NeuroMolecular Med. 2007; 9(1): 1–16. PubMed Abstract | Publisher Full Text
89. Cole SL, Vassar R: Isoprenoids and Alzheimer’s disease: a complex relationship. Neurobiol. Dis. 2006; 22(2): 209–222. Publisher Full Text
90. McGeer EG, McGeer PL: Clinically tested drugs for Alzheimer’s disease. Expert Opin. Investig. Drugs. 2003; 12(7): 1143–1151. Publisher Full Text
91. Xue M, Yong VW: Neuroinflammation in intracerebral haemorrhage: immunotherapies with potential for translation. Lancet Neurol. 2020; 19(12): 1023–1032. PubMed Abstract | Publisher Full Text
92. Saleh AY: Statins as Neuroinflammatory Therapy, Bibliometric Study. figshare. Figure. 2024. Publisher Full Text
93. Saleh AY: Open Science Framework: PRISMA checklist & Flow Diagram: Transcutaneous stimulation as a niche theme in gastroparesis therapy. Dataset. figshare. 2024. Publisher Full Text
94. van Eck NJ , Waltman L: Citation-based clustering of publications using CitNetExplorer and VOSviewer. Scientometrics. 2017; 111(2): 1053–1070. PubMed Abstract | Publisher Full Text

Comments on this article Comments (1)

Version 1

VERSION 1 PUBLISHED 23 Aug 2024

Reader Comment 24 Aug 2024

Abdul Wasay Sherazi, Pharmacy practice, Bahauddin Zakariya University, Multan, Pakistan

24 Aug 2024

Reader Comment
The abstract presents an interesting topic, focusing on the use of statins as a therapeutic option for neuroinflammatory conditions through a bibliometric study. However, there are several areas where the ... Continue reading
The abstract presents an interesting topic, focusing on the use of statins as a therapeutic option for neuroinflammatory conditions through a bibliometric study. However, there are several areas where the abstract could be improved:

Clarity and Focus:

The introduction of the abstract lacks clarity regarding the connection between neuroinflammation, neurodegenerative diseases, and the role of statins. It would be beneficial to elaborate more on how statins influence neuroinflammation and neurodegenerative diseases.

The objective of the study is clear but could be more precise. For example, instead of saying "providing valuable insights into research development and future research questions," the abstract could specify what kind of insights or research directions are anticipated.

Methods:

The methodology mentions the use of Biblioshiny and VOSviewer software for data analysis, but it is unclear what specific data or metrics were analyzed. Providing a brief description of the type of data (e.g., number of publications, citation trends, co-authorship networks) would strengthen the abstract.

Results:

The results section lists various trends and analyses but does not provide any specific findings or key insights derived from these analyses. Including one or two significant results or trends would give the reader a better understanding of the study’s impact.

Conclusions:

The conclusions are general and do not reflect the specific findings of the study. Adding a statement about the main trends observed or the most critical gap identified in the literature would make the conclusions more robust and informative.
The abstract presents an interesting topic, focusing on the use of statins as a therapeutic option for neuroinflammatory conditions through a bibliometric study. However, there are several areas where the abstract could be improved:

Clarity and Focus:

The introduction of the abstract lacks clarity regarding the connection between neuroinflammation, neurodegenerative diseases, and the role of statins. It would be beneficial to elaborate more on how statins influence neuroinflammation and neurodegenerative diseases.

The objective of the study is clear but could be more precise. For example, instead of saying "providing valuable insights into research development and future research questions," the abstract could specify what kind of insights or research directions are anticipated.

Methods:

The methodology mentions the use of Biblioshiny and VOSviewer software for data analysis, but it is unclear what specific data or metrics were analyzed. Providing a brief description of the type of data (e.g., number of publications, citation trends, co-authorship networks) would strengthen the abstract.

Results:

The results section lists various trends and analyses but does not provide any specific findings or key insights derived from these analyses. Including one or two significant results or trends would give the reader a better understanding of the study’s impact.

Conclusions:

The conclusions are general and do not reflect the specific findings of the study. Adding a statement about the main trends observed or the most critical gap identified in the literature would make the conclusions more robust and informative.
Competing Interests: No competing interest. Close
Report a concern
Comment

Author details Author details

¹ Neurology, Universitas Pembangunan Nasional Veteran Jakarta, Jakarta, Special Capital Region of Jakarta, 12450, Indonesia
² Family Medicine and Primary Care, Universitas Pelita Harapan, Tangerang, Banten, Indonesia
³ Public Health Sciences, Universitas Pembangunan Nasional Veteran Jakarta, Jakarta, Special Capital Region of Jakarta, 12450, Indonesia

ARMAN YURISALDI SALEH
Roles: Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Investigation, Methodology, Project Administration, Resources, Software, Supervision, Validation, Visualization, Writing – Original Draft Preparation

Tirta Darmawan Susanto
Roles: Writing – Original Draft Preparation, Writing – Review & Editing

Riezky Valentina
Roles: Writing – Review & Editing

Dwi Arwandi Yogi Saputra
Roles: Writing – Review & Editing

Competing interests

No competing interests were disclosed.

Grant information

The author(s) declared that no grants were involved in supporting this work.

Article Versions (1)

version 1

Published: 23 Aug 2024, 13:959

https://doi.org/10.12688/f1000research.152963.1

Copyright

© 2024 SALEH AY et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download

Export To

metrics

	Views	Downloads
F1000Research	-	-
PubMed Central Data from PMC are received and updated monthly.	-	-

Citations

0

SEE MORE DETAILS

CITE

how to cite this article

SALEH AY, Susanto TD, Valentina R and Saputra DAY. Statins as Neuroinflammatory Therapy, Bibliometric Study [version 1; peer review: awaiting peer review]. F1000Research 2024, 13:959 (https://doi.org/10.12688/f1000research.152963.1)

NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article.

track

receive updates on this article

Track an article to receive email alerts on any updates to this article.

Open Peer Review

Comments on this article Comments (1)

Version 1

VERSION 1 PUBLISHED 23 Aug 2024

Reader Comment 24 Aug 2024

Abdul Wasay Sherazi, Pharmacy practice, Bahauddin Zakariya University, Multan, Pakistan

24 Aug 2024

Reader Comment
The abstract presents an interesting topic, focusing on the use of statins as a therapeutic option for neuroinflammatory conditions through a bibliometric study. However, there are several areas where the ... Continue reading
The abstract presents an interesting topic, focusing on the use of statins as a therapeutic option for neuroinflammatory conditions through a bibliometric study. However, there are several areas where the abstract could be improved:

Clarity and Focus:

The introduction of the abstract lacks clarity regarding the connection between neuroinflammation, neurodegenerative diseases, and the role of statins. It would be beneficial to elaborate more on how statins influence neuroinflammation and neurodegenerative diseases.

The objective of the study is clear but could be more precise. For example, instead of saying "providing valuable insights into research development and future research questions," the abstract could specify what kind of insights or research directions are anticipated.

Methods:

The methodology mentions the use of Biblioshiny and VOSviewer software for data analysis, but it is unclear what specific data or metrics were analyzed. Providing a brief description of the type of data (e.g., number of publications, citation trends, co-authorship networks) would strengthen the abstract.

Results:

The results section lists various trends and analyses but does not provide any specific findings or key insights derived from these analyses. Including one or two significant results or trends would give the reader a better understanding of the study’s impact.

Conclusions:

The conclusions are general and do not reflect the specific findings of the study. Adding a statement about the main trends observed or the most critical gap identified in the literature would make the conclusions more robust and informative.
The abstract presents an interesting topic, focusing on the use of statins as a therapeutic option for neuroinflammatory conditions through a bibliometric study. However, there are several areas where the abstract could be improved:

Clarity and Focus:

The introduction of the abstract lacks clarity regarding the connection between neuroinflammation, neurodegenerative diseases, and the role of statins. It would be beneficial to elaborate more on how statins influence neuroinflammation and neurodegenerative diseases.

The objective of the study is clear but could be more precise. For example, instead of saying "providing valuable insights into research development and future research questions," the abstract could specify what kind of insights or research directions are anticipated.

Methods:

The methodology mentions the use of Biblioshiny and VOSviewer software for data analysis, but it is unclear what specific data or metrics were analyzed. Providing a brief description of the type of data (e.g., number of publications, citation trends, co-authorship networks) would strengthen the abstract.

Results:

The results section lists various trends and analyses but does not provide any specific findings or key insights derived from these analyses. Including one or two significant results or trends would give the reader a better understanding of the study’s impact.

Conclusions:

The conclusions are general and do not reflect the specific findings of the study. Adding a statement about the main trends observed or the most critical gap identified in the literature would make the conclusions more robust and informative.
Competing Interests: No competing interest. Close
Report a concern
Comment

Open Peer Review

Reviewer Status

AWAITING PEER REVIEW

Comments on this article

All Comments(1)

Add a comment

Sign up for content alerts

Browse by related subjects

[1] 1. Janciauskiene S, Sun YX, Wright HT: Interactions of A beta with endogenous anti-inflammatory agents: a basis for chronic neuroinflammation in Alzheimer’s disease. Neurobiol. Dis. 2002; 10(3): 187–200. PubMed Abstract | Publisher Full Text

[2] 2. Gholamalizadeh H, Ensan B, Sukhorukov VN, et al.: Targeting the CCL2-CCR2 signaling pathway: potential implications of statins beyond cardiovascular diseases. J. Pharm. Pharmacol. 2024; 76(2): 138–153. PubMed Abstract | Publisher Full Text

[3] 3. Greenwood J, Walters CE, Pryce G, et al.: Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis. FASEB J. 2003; 17(8): 905–907. PubMed Abstract | Publisher Full Text

[4] 4. Alam A, Hana Z, Jin Z, et al.: Surgery, neuroinflammation and cognitive impairment. EBioMedicine. 2018; 37: 547–556. PubMed Abstract | Publisher Full Text | Free Full Text

[5] 5. Xu X, Gao W, Cheng S, et al.: Anti-inflammatory and immunomodulatory mechanisms of atorvastatin in a murine model of traumatic brain injury. J. Neuroinflammation. 2017; 14(1): 167. PubMed Abstract | Publisher Full Text | Free Full Text

[6] 6. Turowski P, Adamson P, Greenwood J: Pharmacological targeting of ICAM-1 signaling in brain endothelial cells: potential for treating neuroinflammation. Cell. Mol. Neurobiol. 2005; 25(1): 153–170. PubMed Abstract | Publisher Full Text

[7] 7. Adamson P, Greenwood J: How do statins control neuroinflammation? Inflamm. Res. 2003; 52(10): 399–403. Publisher Full Text

[8] 8. Marques NF, Castro AA, Mancini G, et al.: Atorvastatin Prevents Early Oxidative Events and Modulates Inflammatory Mediators in the Striatum Following Intranasal 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Administration in Rats. Neurotox. Res. 2018; 33(3): 549–559. PubMed Abstract | Publisher Full Text

[9] 9. Santos DB, Colle D, Moreira EL, et al.: Succinobucol, a Non-Statin Hypocholesterolemic Drug, Prevents Premotor Symptoms and Nigrostriatal Neurodegeneration in an Experimental Model of Parkinson’s Disease. Mol. Neurobiol. 2017; 54(2): 1513–1530. PubMed Abstract | Publisher Full Text

[10] 10. Castro AA, Wiemes BP, Matheus FC, et al.: Atorvastatin improves cognitive, emotional and motor impairments induced by intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in rats, an experimental model of Parkinson’s disease. Brain Res. 2013; 1513: 103–116. PubMed Abstract | Publisher Full Text

[11] 11. Zhou X, Wu X, Wang R, et al.: Mechanisms of 3-Hydroxyl 3-Methylglutaryl CoA Reductase in Alzheimer’s Disease. Int. J. Mol. Sci. 2023; 25(1). PubMed Abstract | Publisher Full Text | Free Full Text

[12] 12. Weekman EM, Johnson SN, Rogers CB, et al.: Atorvastatin rescues hyperhomocysteinemia-induced cognitive deficits and neuroinflammatory gene changes. J. Neuroinflammation. 2023; 20(1): 199. PubMed Abstract | Publisher Full Text | Free Full Text

[13] 13. Zahedi E, Sanaeierad A, Nikbakhtzadeh M, et al.: Simvastatin improves learning and memory impairment via gut-brain axis regulation in an ovariectomized/D-galactose Alzheimer’s rat model. Behav. Brain Res. 2023; 453: 114611. PubMed Abstract | Publisher Full Text

[14] 14. Alsubaie N, Al-Kuraishy HM, Al-Gareeb AI, et al.: Statins Use in Alzheimer Disease: Bane or Boon from Frantic Search and Narrative Review. Brain Sci. 2022; 12(10). PubMed Abstract | Publisher Full Text | Free Full Text

[15] 15. Arbo BD, Schimith LE, Goulart Dos Santos M, et al.: Repositioning and development of new treatments for neurodegenerative diseases: Focus on neuroinflammation. Eur. J. Pharmacol. 2022; 919: 174800. PubMed Abstract | Publisher Full Text

[16] 16. Gamba P, Giannelli S, Staurenghi E, et al.: The Controversial Role of 24-S-Hydroxycholesterol in Alzheimer’s Disease. Antioxidants (Basel). 2021; 10(5). Publisher Full Text

[17] 17. Sallustio F, Studer V: Targeting New Pharmacological Approaches for Alzheimer’s Disease: Potential for Statins and Phosphodiesterase Inhibitors. CNS Neurol. Disord. Drug Targets. 2016; 15(6): 647–659. PubMed Abstract | Publisher Full Text

[18] 18. Xia W, Mo H: Potential of tocotrienols in the prevention and therapy of Alzheimer’s disease. J. Nutr. Biochem. 2016; 31: 1–9. PubMed Abstract | Publisher Full Text

[19] 19. de la Monte SM : Therapeutic targets of brain insulin resistance in sporadic Alzheimer’s disease. Front. Biosci. (Elite Ed.). 2012; 4(4): 1582–1605. PubMed Abstract | Publisher Full Text

[20] 20. Pac-Soo C, Lloyd DG, Vizcaychipi MP, et al.: Statins: the role in the treatment and prevention of Alzheimer’s neurodegeneration. J. Alzheimers Dis. 2011; 27(1): 1–10. PubMed Abstract | Publisher Full Text

[21] 21. Giunta B, Rezai-Zadeh K, Tan J: Impact of the CD40-CD40L dyad in Alzheimer’s disease. CNS Neurol. Disord. Drug Targets. 2010; 9(2): 149–155. PubMed Abstract | Publisher Full Text | Free Full Text

[22] 22. Scarpini E, Cogiamanian F: Alzheimer’s disease: from molecular pathogenesis to innovative therapies. Expert. Rev. Neurother. 2003; 3(5): 619–630. Publisher Full Text

[23] 23. Silva T, Teixeira J, Remião F, et al.: Alzheimer’s disease, cholesterol, and statins: the junctions of important metabolic pathways. Angew. Chem. Int. Ed. Engl. 2013; 52(4): 1110–1121. PubMed Abstract | Publisher Full Text

[24] 24. Alruwaili M, Al-Kuraishy HM, Alexiou A, et al.: Pathogenic Role of Fibrinogen in the Neuropathology of Multiple Sclerosis: A Tale of Sorrows and Fears. Neurochem. Res. 2023; 48(11): 3255–3269. PubMed Abstract | Publisher Full Text | Free Full Text

[25] 25. Luccarini I, Ballerini C, Biagioli T, et al.: Combined treatment with atorvastatin and minocycline suppresses severity of EAE. Exp. Neurol. 2008; 211(1): 214–226. PubMed Abstract | Publisher Full Text

[26] 26. Lopez-Lopez A, Valenzuela R, Rodriguez-Perez AI, et al.: Interactions between Angiotensin Type-1 Antagonists, Statins, and ROCK Inhibitors in a Rat Model of L-DOPA-Induced Dyskinesia. Antioxidants (Basel). 2023; 12(7). Publisher Full Text

[27] 27. Vigne S, Duc D, Peter B, et al.: Lowering blood cholesterol does not affect neuroinflammation in experimental autoimmune encephalomyelitis. J. Neuroinflammation. 2022; 19(1): 42. PubMed Abstract | Publisher Full Text | Free Full Text

[28] 28. Prado DS, Damasceno LEA, Sonego AB, et al.: Pitavastatin ameliorates autoimmune neuroinflammation by regulating the Treg/Th17 cell balance through inhibition of mevalonate metabolism. Int. Immunopharmacol. 2021; 91: 107278. PubMed Abstract | Publisher Full Text

[29] 29. Singh I, Samuvel DJ, Choi S, et al.: Combination therapy of lovastatin and AMP-activated protein kinase activator improves mitochondrial and peroxisomal functions and clinical disease in experimental autoimmune encephalomyelitis model. Immunology. 2018; 154(3): 434–451. PubMed Abstract | Publisher Full Text | Free Full Text

[30] 30. de Oliveira DM , de Oliveira EM , Ferrari Mde F, et al.: Simvastatin ameliorates experimental autoimmune encephalomyelitis by inhibiting Th1/Th17 response and cellular infiltration. Inflammopharmacology. 2015; 23(6): 343–354. PubMed Abstract | Publisher Full Text

[31] 31. Murugesan N, Paul D, Lemire Y, et al.: Active induction of experimental autoimmune encephalomyelitis by MOG35-55 peptide immunization is associated with differential responses in separate compartments of the choroid plexus. Fluids Barriers CNS. 2012; 9(1): 15. PubMed Abstract | Publisher Full Text | Free Full Text

[32] 32. Paintlia AS, Paintlia MK, Singh AK, et al.: Inhibition of rho family functions by lovastatin promotes myelin repair in ameliorating experimental autoimmune encephalomyelitis. Mol. Pharmacol. 2008; 73(5): 1381–1393. PubMed Abstract | Publisher Full Text | Free Full Text

[33] 33. Singh I, Paintlia AS, Khan M, et al.: Impaired peroxisomal function in the central nervous system with inflammatory disease of experimental autoimmune encephalomyelitis animals and protection by lovastatin treatment. Brain Res. 2004; 1022(1-2): 1–11. PubMed Abstract | Publisher Full Text

[34] 34. Xu B, Zhou Y, Zhang Z, et al.: Serum concentrations of NLRP3 in relation to functional outcome and delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. Clin. Chim. Acta. 2022; 536: 61–69. PubMed Abstract | Publisher Full Text

[35] 35. Mir MA, Albaradie RS: Inflammatory Mechanisms as Potential Therapeutic Targets in Stroke. Adv. Neuroimmune Biol. 2014; 5: 199–216. Publisher Full Text

[36] 36. Simani L, Naderi N, Khodagholi F, et al.: Association of Long-Term Atorvastatin with Escalated Stroke-Induced Neuroinflammation in Rats. J. Mol. Neurosci. 2017; 61(1): 32–41. PubMed Abstract | Publisher Full Text

[37] 37. Gonçalves CA, Sesterheim P, Wartchow KM, et al.: Why antidiabetic drugs are potentially neuroprotective during the Sars-CoV-2 pandemic: The focus on astroglial UPR and calcium-binding proteins. Front. Cell. Neurosci. 2022; 16: 905218. PubMed Abstract | Publisher Full Text | Free Full Text

[38] 38. Zhang J, Hao N, Li W, et al.: Simvastatin Upregulates Lipoxin A4 and Accelerates Neuroinflammation Resolution After Intracerebral Hemorrhage. Curr. Neurovasc. Res. 2022; 19(3): 321–332. PubMed Abstract | Publisher Full Text

[39] 39. Zhang R, Xue M, Yong VW: Central Nervous System Tissue Regeneration after Intracerebral Hemorrhage: The Next Frontier. Cells. 2021; 10(10). PubMed Abstract | Publisher Full Text | Free Full Text

[40] 40. Zi L, Zhou W, Xu J, et al.: Rosuvastatin Nanomicelles Target Neuroinflammation and Improve Neurological Deficit in a Mouse Model of Intracerebral Hemorrhage. Int. J. Nanomedicine. 2021; 16: 2933–2947. PubMed Abstract | Publisher Full Text | Free Full Text

[41] 41. Zhang J, Shi X, Hao N, et al.: Simvastatin Reduces Neutrophils Infiltration Into Brain Parenchyma After Intracerebral Hemorrhage via Regulating Peripheral Neutrophils Apoptosis. Front. Neurosci. 2018; 12: 977. PubMed Abstract | Publisher Full Text | Free Full Text

[42] 42. Indraswari F, Wang H, Lei B, et al.: Statins improve outcome in murine models of intracranial hemorrhage and traumatic brain injury: a translational approach. J. Neurotrauma. 2012; 29(7): 1388–1400. PubMed Abstract | Publisher Full Text

[43] 43. James RF, Kramer DR, Aljuboori ZS, et al.: Novel Treatments in Neuroprotection for Aneurysmal Subarachnoid Hemorrhage. Curr. Treat. Options Neurol. 2016; 18(8): 38. Publisher Full Text

[44] 44. Chen J, Wang Y, Hu X, et al.: The Role of Statins in the Management of Delirium: Recent Advances. CNS Neurol. Disord. Drug Targets. 2021; 20(3): 203–215. PubMed Abstract | Publisher Full Text

[45] 45. Mariscalco G, Mariani S, Biancari F, et al.: Effects of statins on delirium following cardiac surgery - evidence from literature. Psychiatr. Pol. 2015; 49(6): 1359–1370. PubMed Abstract | Publisher Full Text

[46] 46. Taburyanskaya M, Hassig T: Statins and delirium: is there a role? Curr. Atheroscler. Rep. 2015; 17(1): 470. PubMed Abstract | Publisher Full Text

[47] 47. Page VJ, Davis D, Zhao XB, et al.: Statin use and risk of delirium in the critically ill. Am. J. Respir. Crit. Care Med. 2014; 189(6): 666–673. PubMed Abstract | Publisher Full Text | Free Full Text

[48] 48. Morandi A, Hughes CG, Girard TD, et al.: Statins and brain dysfunction: a hypothesis to reduce the burden of cognitive impairment in patients who are critically ill. Chest. 2011; 140(3): 580–585. PubMed Abstract | Publisher Full Text | Free Full Text

[49] 49. Catalão CHR, Santos-Junior NN, da Costa LHA , et al.: Simvastatin Prevents Long-Term Cognitive Deficits in Sepsis Survivor Rats by Reducing Neuroinflammation and Neurodegeneration. Neurotox. Res. 2020; 38(4): 871–886. PubMed Abstract | Publisher Full Text

[50] 50. McFarland AJ, Davey AK, McDermott CM, et al.: Differences in statin associated neuroprotection corresponds with either decreased production of IL-1β or TNF-α in an in vitro model of neuroinflammation-induced neurodegeneration. Toxicol. Appl. Pharmacol. 2018; 344: 56–73. PubMed Abstract | Publisher Full Text

[51] 51. Clementino AR, Marchi C, Pozzoli M, et al.: Anti-Inflammatory Properties of Statin-Loaded Biodegradable Lecithin/Chitosan Nanoparticles: A Step Toward Nose-to-Brain Treatment of Neurodegenerative Diseases. Front. Pharmacol. 2021; 12: 716380. PubMed Abstract | Publisher Full Text | Free Full Text

[52] 52. Bagheri H, Ghasemi F, Barreto GE, et al.: The effects of statins on microglial cells to protect against neurodegenerative disorders: A mechanistic review. Biofactors. 2020; 46(3): 309–325. PubMed Abstract | Publisher Full Text

[53] 53. Ian HH, Joanne R, Stephane H, et al.: STAREE-Mind Imaging Study: a randomised placebo-controlled trial of atorvastatin for prevention of cerebrovascular decline and neurodegeneration in older individuals. BMJ Neurol. Open. 2023; 5(2): e000541. Publisher Full Text

[54] 54. González-Guevara E, Cárdenas G, Pérez-Severiano F, et al.: Dysregulated Brain Cholesterol Metabolism Is Linked to Neuroinflammation in Huntington’s Disease. Mov. Disord. 2020; 35(7): 1113–1127. PubMed Abstract | Publisher Full Text

[55] 55. Hai-Na Z, Xu-Ben Y, Cong-Rong T, et al.: Atorvastatin ameliorates depressive behaviors and neuroinflammatory in streptozotocin-induced diabetic mice. Psychopharmacology. 2020; 237(3): 695–705. PubMed Abstract | Publisher Full Text

[56] 56. Yu XB, Zhang HN, Dai Y, et al.: Simvastatin prevents and ameliorates depressive behaviors via neuroinflammatory regulation in mice. J. Affect. Disord. 2019; 245: 939–949. PubMed Abstract | Publisher Full Text

[57] 57. de Jesus Oliveira FM , Gonçalves-de-Albuquerque CF, de Moraes IMM , et al.: Simvastatin Posttreatment Controls Inflammation and Improves Bacterial Clearance in Experimental Sepsis. Mediat. Inflamm. 2020; 2020: 1839762.

[58] 58. Lokhandwala A, Hanna K, Gries L, et al.: Preinjury Statins Are Associated With Improved Survival in Patients With Traumatic Brain Injury. J. Surg. Res. 2020; 245: 367–372. PubMed Abstract | Publisher Full Text

[59] 59. Wible EF, Laskowitz DT: Statins in traumatic brain injury. Neurotherapeutics. 2010; 7(1): 62–73. PubMed Abstract | Publisher Full Text | Free Full Text

[60] 60. Barus R, Béné J, Deguil J, et al.: Drug interactions with dementia-related pathophysiological pathways worsen or prevent dementia. Br. J. Pharmacol. 2019; 176(18): 3413–3434. PubMed Abstract | Publisher Full Text | Free Full Text

[61] 61. Petek B, Villa-Lopez M, Loera-Valencia R, et al.: Connecting the brain cholesterol and renin-angiotensin systems: potential role of statins and RAS-modifying medications in dementia. J. Intern. Med. 2018; 284(6): 620–642. PubMed Abstract | Publisher Full Text

[62] 62. Li X-L, Li H, Zhang M, et al.: Correction to: Exosomes derived from atorvastatin-modified bone marrow dendritic cells ameliorate experimental autoimmune myasthenia gravis by up-regulated levels of IDO/Treg and partly dependent on FasL/Fas pathway. J. Neuroinflammation. 2019; 16(1): 119. PubMed Abstract | Publisher Full Text | Free Full Text

[63] 63. Ekladious ST, El Sayed NS: Effect of pioglitazone and simvastatin in lipopolysaccharide-induced amyloidogenesis and cognitive impairment in mice: possible role of glutamatergic pathway and oxidative stress. Behav. Pharmacol. 2019; 30(1): 5–15. PubMed Abstract | Publisher Full Text

[64] 64. Fang SC, Xie H, Chen F, et al.: Simvastatin ameliorates memory impairment and neurotoxicity in streptozotocin-induced diabetic mice. Neuroscience. 2017; 355: 200–211. PubMed Abstract | Publisher Full Text

[65] 65. Reis PA, Estato V, da Silva TI , et al.: Statins decrease neuroinflammation and prevent cognitive impairment after cerebral malaria. PLoS Pathog. 2012; 8(12): e1003099. PubMed Abstract | Publisher Full Text | Free Full Text

[66] 66. Kurata T, Miyazaki K, Kozuki M, et al.: Atorvastatin and pitavastatin improve cognitive function and reduce senile plaque and phosphorylated tau in aged APP mice. Brain Res. 2011; 1371: 161–170. PubMed Abstract | Publisher Full Text

[67] 67. Reis PA, Alexandre PCB, D’Avila JC, et al.: Statins prevent cognitive impairment after sepsis by reverting neuroinflammation, and microcirculatory/endothelial dysfunction. Brain Behav. Immun. 2017; 60: 293–303. PubMed Abstract | Publisher Full Text

[68] 68. Xu TC, Lv Y, Liu QY, et al.: Long-term atorvastatin improves cognitive decline by regulating gut function in naturally ageing rats. Immun. Ageing. 2022; 19(1): 52. PubMed Abstract | Publisher Full Text | Free Full Text

[69] 69. Quintana-Pájaro LJ, Ramos-Villegas Y, Cortecero-Sabalza E, et al.: The Effect of Statins in Epilepsy: A Systematic Review. J. Neurosci. Rural Pract. 2018; 9(4): 478–486. PubMed Abstract | Publisher Full Text

[70] 70. Jin Z, Jung Y, Yi CO, et al.: Atorvastatin pretreatment attenuates kainic acid-induced hippocampal neuronal death via regulation of lipocalin-2-associated neuroinflammation. Korean J. Physiol. Pharmacol. 2018; 22(3): 301–309. PubMed Abstract | Publisher Full Text | Free Full Text

[71] 71. Oliveira CV, Grigoletto J, Canzian JM, et al.: Effect of atorvastatin on behavioral alterations and neuroinflammation during epileptogenesis. Epilepsy Behav. 2018; 78: 109–117. PubMed Abstract | Publisher Full Text

[72] 72. Shafaroodi H, Moezi L, Fakhrzad A, et al.: The involvement of nitric oxide in the anti-seizure effect of acute atorvastatin treatment in mice. Neurol. Res. 2012; 34(9): 847–853. PubMed Abstract | Publisher Full Text

[73] 73. Gouveia TL, Scorza FA, Iha HA, et al.: Lovastatin decreases the synthesis of inflammatory mediators during epileptogenesis in the hippocampus of rats submitted to pilocarpine-induced epilepsy. Epilepsy Behav. 2014; 36: 68–73. PubMed Abstract | Publisher Full Text

[74] 74. Dar K, Kapucu A, Acar S, et al.: Evaluation of Antiepileptogenic Effect of Atorvastatin on Development of Pentylenetetrazole Induced Kindling in Rats: The Responsibility of Inducible Nitric Oxide Synthase and Metalloproteinase 2. Turk. Klin. J. Med. Sci. 2013; 33: 995–1006. Publisher Full Text

[75] 75. Carroll JA, Race B, Phillips K, et al.: Statins are ineffective at reducing neuroinflammation or prolonging survival in scrapie-infected mice. J. Gen. Virol. 2017; 98(8): 2190–2199. PubMed Abstract | Publisher Full Text | Free Full Text

[76] 76. McFarland AJ, Davey AK, Anoopkumar-Dukie S: Statins Reduce Lipopolysaccharide-Induced Cytokine and Inflammatory Mediator Release in an in vitro Model of Microglial-Like Cells. Mediat. Inflamm. 2017; 2017: 2582745.

[77] 77. Li W, Li Y, Zhu S, et al.: Rosuvastatin attenuated the existing morphine tolerance in rats with L5 spinal nerve transection through inhibiting activation of astrocytes and phosphorylation of ERK42/44. Neurosci. Lett. 2015; 584: 314–319. PubMed Abstract | Publisher Full Text

[78] 78. Farooqui AA, Ong WY, Horrocks LA, et al.: Comparison of biochemical effects of statins and fish oil in brain: the battle of the titans. Brain Res. Rev. 2007; 56(2): 443–471. PubMed Abstract | Publisher Full Text

[79] 79. Mohamed DI, Alaa El-Din Aly El-Waseef D, Nabih ES, et al.: Acetylsalicylic Acid Suppresses Alcoholism-Induced Cognitive Impairment Associated with Atorvastatin Intake by Targeting Cerebral miRNA155 and NLRP3: In Vivo, and In Silico Study. Pharmaceutics. 2022; 14(3). PubMed Abstract | Publisher Full Text | Free Full Text

[80] 80. Ong WY, Go ML, Wang DY, et al.: Effects of Antimalarial Drugs on Neuroinflammation-Potential Use for Treatment of COVID-19-Related Neurologic Complications. Mol. Neurobiol. 2021; 58(1): 106–117. PubMed Abstract | Publisher Full Text | Free Full Text

[81] 81. Ma G, Pan Z, Kong L, et al.: Neuroinflammation in hemorrhagic transformation after tissue plasminogen activator thrombolysis: Potential mechanisms, targets, therapeutic drugs and biomarkers. Int. Immunopharmacol. 2021; 90: 107216. PubMed Abstract | Publisher Full Text

[82] 82. Tauber SC, Djukic M, Gossner J, et al.: Sepsis-associated encephalopathy and septic encephalitis: an update. Expert Rev. Anti-Infect. Ther. 2021; 19(2): 215–231. PubMed Abstract | Publisher Full Text

[83] 83. Starhof C, Hejl AM, Korbo L, et al.: Risk of Multiple System Atrophy and the Use of Anti-Inflammatory Drugs: A Danish Register-Based Case-Control Study. Neuroepidemiology. 2020; 54(1): 58–63. PubMed Abstract | Publisher Full Text

[84] 84. Nasoohi S, Simani L, Khodagholi F, et al.: Coenzyme Q10 supplementation improves acute outcomes of stroke in rats pretreated with atorvastatin. Nutr. Neurosci. 2019; 22(4): 264–272. PubMed Abstract | Publisher Full Text

[85] 85. Shetty AK, Upadhya R, Madhu LN, et al.: Novel Insights on Systemic and Brain Aging, Stroke, Amyotrophic Lateral Sclerosis, and Alzheimer’s Disease. Aging Dis. 2019; 10(2): 470–482. PubMed Abstract | Publisher Full Text | Free Full Text

[86] 86. Marcuzzi A, Piscianz E, Zweyer M, et al.: Geranylgeraniol and Neurological Impairment: Involvement of Apoptosis and Mitochondrial Morphology. Int. J. Mol. Sci. 2016; 17(3): 365. PubMed Abstract | Publisher Full Text | Free Full Text

[87] 87. Celsi F, Piscianz E, Romano M, et al.: Knockdown of MVK does not lead to changes in NALP3 expression or activation. J. Inflamm. (Lond). 2015; 12: 7. PubMed Abstract | Publisher Full Text | Free Full Text

[88] 88. Korn T, Rao M, Magnus T: Autoimmune modulation of astrocyte-mediated homeostasis. NeuroMolecular Med. 2007; 9(1): 1–16. PubMed Abstract | Publisher Full Text

[89] 89. Cole SL, Vassar R: Isoprenoids and Alzheimer’s disease: a complex relationship. Neurobiol. Dis. 2006; 22(2): 209–222. Publisher Full Text

[90] 90. McGeer EG, McGeer PL: Clinically tested drugs for Alzheimer’s disease. Expert Opin. Investig. Drugs. 2003; 12(7): 1143–1151. Publisher Full Text

[91] 91. Xue M, Yong VW: Neuroinflammation in intracerebral haemorrhage: immunotherapies with potential for translation. Lancet Neurol. 2020; 19(12): 1023–1032. PubMed Abstract | Publisher Full Text

[92] 92. Saleh AY: Statins as Neuroinflammatory Therapy, Bibliometric Study. figshare. Figure. 2024. Publisher Full Text

[93] 93. Saleh AY: Open Science Framework: PRISMA checklist & Flow Diagram: Transcutaneous stimulation as a niche theme in gastroparesis therapy. Dataset. figshare. 2024. Publisher Full Text

[94] 94. van Eck NJ , Waltman L: Citation-based clustering of publications using CitNetExplorer and VOSviewer. Scientometrics. 2017; 111(2): 1053–1070. PubMed Abstract | Publisher Full Text

Statins as Neuroinflammatory Therapy, Bibliometric Study

Abstract

Introduction

Methods

Results

Conclusions

Keywords

Introduction

Methods

Data collection

Data analysis

Quantitative analysis

Figure 1. Documents by year.

Figure 2. Most global cited documents.

Figure 3. Most relevant sources.

Figure 4. Factorial map of the documents with the highest contributes.

Figure 5. Documents by author.

Figure 6. Most relevant affiliations.

Figure 7. Documents by subject area.

Figure 8. Trend topic.

Figure 9. Network visualization.

Figure 10. Overlay visualization of scopus, database using Vosviewer.

Figure 11. Density visualization.

Figure 12. Thematic map.

Figure 13. Thematic evolution.

Qualitative analysis

Figure 14. Word cloud.

Discussion

Conclusion

Author contribution

Data availability statement

Underlying data

Extended data

Reporting guidelines

Software availability

References

Comments on this article Comments (1)

Open Peer Review

Comments on this article Comments (1)

Open Peer Review

Reviewer Status

Comments on this article

Browse by related subjects

Competing Interests Policy

Stay Updated